Single Agent Chemotherapy Market Worth $8.2 Billion By 2030: IndustryARC

Single Agent Chemotherapy Market size is expected to reach $8.2 billion by 2030 after growing at a CAGR of 3.9% during the forecast period 2024-2030, according to the latest market research report published by IndustryARC. Increasing incidence of cancer, government investments in healthcare infrastructure, advances in drug development, the approval of new single agent chemotherapeutic drugs and the increasing investment in healthcare are set to drive the Single Agent Chemotherapy market, finds IndustryARC in its recent report, titled “Single Agent Chemotherapy Market - By Drug Class (Alkylating Agents, Antimetabolites , Anti-tumor Antibiotics, Topoisomerase Inhibitors, Mitotic Inhibitors, Others), By Cancer (Breast Cancer, Lung Cancer, Colorectal Cancer, Leukemia, Lymphoma, Others), By Route of Administration (Intravenous (IV), Oral, Subcutaneous (SC), Intramuscular (IM)), By End User (Hospitals & Clinics, Specialty Centers and Others) and By Geography Analysis - Global Opportunity Analysis & Industry Forecast, 2024-2030

The rising prevalence of cancer globally is a significant driver for the single agent chemotherapy market growth. According to the World Health Organisation, globally over 35 million new cancer cases are predicted in 2050, an increase from the estimated 20 million in 2022. With millions of new cancer cases diagnosed annually the demand for effective treatment options continues to escalate. A report by Cancer Research UK states that by 2040 there are projected to be 500,000 new cancer cases diagnosed each year in the UK attributed to a growing and ageing population. Research by the Daffodil Centre, a joint venture of Cancer Council NSW and the University of Sydney, shows that 1.45 million Australians will die of cancer over the 25-year period from 2020-2044. Advances in medical technology and increased awareness have led to more frequent and earlier cancer diagnoses necessitating the need for robust chemotherapy solutions. Single agent chemotherapy offers a targeted approach for various cancers such as breast, lung and colorectal cancers. The aging global population, which is more susceptible to cancer, further propels the market demand.

• Alkylating Agents

• Antimetabolites 

• Anti-tumor Antibiotics

• Topoisomerase Inhibitors

• Mitotic Inhibitors

• Others

• Intravenous (IV)

• Oral

• Subcutaneous (SC)

• Intramuscular (IM))

• Hospitals & Clinics

• Specialty Centers

• Others

• North America

• South America

• Europe

• Asia-Pacific

• Rest of the World

Geographically, North America held the largest share with 35% of the overall market in 2023, owing to the region’s growing incidence of cancer and well-developed healthcare infrastructure. The region boasts leading medical institutions, a high focus on advanced diagnostics and a large aging population requiring constant health monitoring. This fuels demand for innovative single agent chemotherapy drugs. According to the Association of Cancer Society, in 2023, a little over 1.9 million new cases of cancer are expected to be diagnosed in the United States. Prostate cancer is the most common cancer among males (29%), followed by lung (12%) and colorectal (8%) cancers. Among females, breast (31%), lung (13%), and colorectal (8%) cancers are the most common. 

Developing countries are experiencing a period of significant healthcare infrastructure growth. Ever since the pandemic, investments are pouring in from governments and private investors into building new hospitals and upgrading existing facilities. In May 2024, AstraZeneca, a leading pharmaceutical company, announced plans to construct a $1.5 billion state-of-the-art manufacturing facility in Singapore with a focus on producing anti-cancer medication, supported by the Singapore Economic Development Board. In September 2023, the White House announced a $240 million investment to fight cancer, the money will go to researchers working on cancer prevention, detection, treatment and survival projects. Such investments are expected to boost the cancer treatment including the single agent chemotherapy market.

Combination chemotherapy can act as a significant restraint for the single-agent chemotherapy market. This approach utilizes multiple chemotherapeutic agents simultaneously and is often preferred for its ability to target cancer cells through various mechanisms, thereby reducing the likelihood of drug resistance and increasing treatment efficacy. The effectiveness of combination therapy in improving patient outcomes, particularly for aggressive or advanced cancers, can prove to be a challenge for the single-agent treatments.

The expansion of healthcare infrastructure and increasing cancer awareness in emerging markets present a significant growth opportunity for the single-agent chemotherapy market. Many developing regions are witnessing a rise in cancer incidence due to aging populations and lifestyle changes. However, these areas often lack access to advanced cancer treatments. Investment in healthcare facilities, coupled with government initiatives to improve cancer care, is creating a favorable environment for the introduction and adoption of single-agent chemotherapy. Additionally, as these markets become more economically robust, the demand for effective and affordable cancer treatments will rise. Pharmaceutical companies can capitalize on this by entering these emerging markets with cost-effective single-agent chemotherapeutic drugs.

Advancements in personalized medicine present a significant opportunity for the single-agent chemotherapy market. Personalized medicine involves tailoring treatment plans based on the genetic makeup of individual patients allowing for more targeted and effective therapies. By integrating genetic profiling and biomarker analysis, healthcare providers can identify which patients are more likely to respond positively to specific single agent chemotherapeutic drugs. This precision in treatment enhances the efficacy of single agent chemotherapy, reduces adverse side effects and improves overall patient outcomes

• Single Agent Chemotherapy Market size and Forecast 

• Single Agent Chemotherapy Market trends

• Single Agent Chemotherapy Market analysis by drug type

• CAGR of the market during the forecast period 2024-2030

• Value Chain analysis of key stake holders

• Detailed analysis of market drivers and opportunities during the forecast period

• Single Agent Chemotherapy Market size estimation and forecast

• Analysis and predictions on end user behavior and upcoming trends 

• Competitive landscape and Vendor market analysis including offerings, developments, and financials

• Comprehensive analysis of challenges and constraints in the Single Agent Chemotherapy Market

• F. Hoffmann-La Roche AG

• Bristol Myers Squibb

• AbbVie

• Pfizer Inc.

• Janssen Biotech

• GlaxoSmithKline

• Novartis AG

• AstraZeneca

• Teva Pharmaceuticals Industries

• Sanofi S.A

• Astellas Pharma

• Incyte Corporation

• Amgen

• Celegen

• Fresenius Kabi

Oncology Market – Oncology market was valued at $136.7 billion in 2019 and is poised to grow at a CAGR of 11.9% during the forecast period. Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer.

Chemotherapy-Induced Myelosuppression Treatment Market- Single Agent Chemotherapy-Induced Myelosuppression Treatment Market size was valued at $14.3 billion in 2020 and is expected to grow with a CAGR of 3.4% during the forecast period 2021-2026. Myelosuppression is a side effect of cancer treatment in which ability of the bone marrow to produce blood cells is decreased.

IndustryARC primarily focuses on Market Research and Consulting Services specific to Cutting Edge Technologies and Newer Application segments of the market. The company’s Custom Research Services are designed to provide insights into the constant flux in the global demand-supply gap of markets.  

IndustryARC’s goal is to provide the right information required by the stakeholder at the right point in time, in a format which assists an intelligent and informed decision-making process.

Mr. Venkat Reddy

IndustryARC

Email: [email protected]

USA:(+1) 518-282-4727

Web: https://www.industryarc.com

Follow us on: LinkedIn | Facebook | Twitter